Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s FY2018 Net Profit Jumps 22.3% on Merck Deal, Global Brands
May 14, 2019
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
- Sunovion to Push Different Dasotraline Trial Data in FDA Negotiations: Sumitomo Dainippon Chief
May 13, 2019
- Mitsubishi Tanabe Foresees 82% Profit Dip in FY2019 as Gilenya Feud Weighs
May 13, 2019
- 70% of Drug Makers Shave New Grad Hiring, 100-Plus Recruits at Only 3 Firms: Jiho Survey
May 13, 2019
- Eisai Nabs Japan Distribution Rights to MTX SC Injection
May 13, 2019
- Alzheimer's Consortium Selects Elenbecestat, BAN2401 for Prevention Studies
May 13, 2019
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Sunovion’s Schizophrenia Agent Awarded US Breakthrough Therapy Designation
May 13, 2019
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Eisai to Invest 15 Billion Yen to Excavate Innovative Technology; 1st Pact Signed with App Developer
May 10, 2019
- Takeda to Divest Dry Eye Drug to Novartis for US$5.3 Billion
May 9, 2019
- Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
- Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar
May 9, 2019
- Sumitomo Dainippon to Set Up Cell Therapy Hub in San Diego
May 9, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
- Eisai Kicks Off Joint Program with UK Institution to Support Dementia Research
May 9, 2019
- Bioverativ Japan Now Merged into Sanofi
May 8, 2019
- Eisai, Purdue Wind Up Partnership for Insomnia Drug Lemborexant
May 8, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…